2010
DOI: 10.1177/112067211002000604
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Purpose To evaluate the safety and efficacy of intravitreal injection of bevacizumab before vitrectomy in advanced proliferative diabetic retinopathy. Methods A randomized clinical trial was performed on 40 eyes of 40 patients. Inclusion criteria were advanced proliferative diabetic retinopathy with fractional retinal detachment and HbA1c <7%. Patients were randomly assigned into 2 groups. Patients in one group had an intravitreal injection (1.25 mg) of bevacizumab 48 hours before 23-G pars plana vitrectomy … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
23
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(23 citation statements)
references
References 30 publications
0
23
0
Order By: Relevance
“…Recently, advancements in surgical techniques and pharmacological therapies have improved the visual prognosis of IPR. In particular, anti-vascular endothelial growth factor (VEGF) therapies prior to vitrectomy facilitates easier surgery due to their regressive effects on pre-retinal neovascularization 2,3 . On the other hand, several recent reports suggest that anti-VEGF therapy might have vision threatening adverse effects, such as thinning of the neurosensory retina after continuous injections of these drugs 4,5 , and intraocular fibrosis development that can lead to tractional retinal detachment [6][7][8][9] .…”
mentioning
confidence: 99%
“…Recently, advancements in surgical techniques and pharmacological therapies have improved the visual prognosis of IPR. In particular, anti-vascular endothelial growth factor (VEGF) therapies prior to vitrectomy facilitates easier surgery due to their regressive effects on pre-retinal neovascularization 2,3 . On the other hand, several recent reports suggest that anti-VEGF therapy might have vision threatening adverse effects, such as thinning of the neurosensory retina after continuous injections of these drugs 4,5 , and intraocular fibrosis development that can lead to tractional retinal detachment [6][7][8][9] .…”
mentioning
confidence: 99%
“…Routinely diabetic PPV without anti-VEGF pretreatment was always troublesome by intra-operative bleeding. Firstly, hemorrhages make it difficult to perform the delamination and segmentation of the fibrovascular tissue, they usually adhere tightly to retina surface, the removal of these tissues has high risk of iatrogenic retinal breaks 26 ; Secondly, continued intra-operative bleeding may impede adequate endophotocoagulation as poor visualization, increasing the risk of rubeosis iridis and subsequently neovascular glaucoma after surgery; Additionally, difficult-to-control bleeding during surgery wastes plenty of time, which might cause other complications like corneal opacification and poor visualization of the surgical field 27 , all these may result in poor surgical outcome. Our studies showed that pretreatment of anti-VEGF could all significantly reduce the incidence of intra-operative bleeding, Pre-Op more than 14 days achieved the highest SUCRA ranking, while conducting anti-VEGF injection at the end of PPV could not achieve any beneficial effect.…”
Section: Discussionmentioning
confidence: 99%
“…Neovascularization, secondary to PDR, can effectively be reduced [27,28], and surgical visualization can be improved by pre-operative anti-VEGF, which were shown to reduce intra-operative hemorrhaging and facilitate fibrovascular membrane delamination resulting in a lower incidence of iatrogenic breaks [17,19,20,27,29,30].…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies reported a pre-operative injection of intra-vitreal bevacizumab from 1 to 33 days before PPV for PDR-related complications [11,14,15,17,19,20,29,30,35,36] and TRD incidence between 5.2% [31] and 9% [37].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation